Cabaletta Bio (CABA) Competitors $1.44 -0.08 (-5.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.48 +0.05 (+3.13%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. CADL, GLUE, ABEO, RCKT, OLMA, ALT, AVIR, ALLO, ALDX, and CRVSShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Abeona Therapeutics (ABEO), Rocket Pharmaceuticals (RCKT), Olema Pharmaceuticals (OLMA), Altimmune (ALT), Atea Pharmaceuticals (AVIR), Allogene Therapeutics (ALLO), Aldeyra Therapeutics (ALDX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Candel Therapeutics Monte Rosa Therapeutics Abeona Therapeutics Rocket Pharmaceuticals Olema Pharmaceuticals Altimmune Atea Pharmaceuticals Allogene Therapeutics Aldeyra Therapeutics Corvus Pharmaceuticals Cabaletta Bio (NASDAQ:CABA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in CABA or CADL? 13.9% of Candel Therapeutics shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is CABA or CADL more profitable? Cabaletta Bio's return on equity of -78.29% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -78.29% -65.68% Candel Therapeutics N/A -136.74%-63.13% Which has stronger valuation & earnings, CABA or CADL? Candel Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.54-0.57Candel TherapeuticsN/AN/A-$55.18M-$1.34-4.69 Does the media refer more to CABA or CADL? In the previous week, Candel Therapeutics had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Candel Therapeutics and 0 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.00 beat Candel Therapeutics' score of -0.50 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Overall Sentiment Cabaletta Bio Neutral Candel Therapeutics Negative Which has more volatility & risk, CABA or CADL? Cabaletta Bio has a beta of 2.74, indicating that its stock price is 174% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.91, indicating that its stock price is 191% less volatile than the S&P 500. Do analysts rate CABA or CADL? Cabaletta Bio presently has a consensus target price of $14.43, indicating a potential upside of 901.98%. Candel Therapeutics has a consensus target price of $22.00, indicating a potential upside of 249.76%. Given Cabaletta Bio's higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryCandel Therapeutics beats Cabaletta Bio on 7 of the 13 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.13M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.5717.7428.8623.83Price / SalesN/A178.75371.4566.14Price / CashN/A41.9535.4557.96Price / Book0.468.508.265.54Net Income-$115.86M-$55.06M$3.25B$259.28M7 Day Performance-13.25%-3.99%-3.75%-4.67%1 Month Performance-10.00%9.58%4.27%4.37%1 Year Performance-78.54%6.70%25.85%17.91% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio1.7988 of 5 stars$1.44-5.3%$14.43+902.0%-79.1%$77.13MN/A-0.5750Positive NewsUpcoming EarningsCADLCandel Therapeutics2.1899 of 5 stars$6.86-2.3%$22.00+220.8%+13.5%$343.54M$120K-5.1260Gap DownGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.56-2.0%$15.33+176.0%+9.6%$341.69M$75.62M69.4590ABEOAbeona Therapeutics3.8493 of 5 stars$6.60+1.1%$19.25+191.5%+34.9%$337.79MN/A-5.2090News CoverageRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.11-1.1%$17.87+475.4%-86.5%$331.57MN/A-1.18240Trending NewsUpcoming EarningsOLMAOlema Pharmaceuticals2.0955 of 5 stars$4.83+2.6%$24.50+407.0%-67.6%$330.61MN/A-2.4070Positive NewsUpcoming EarningsALTAltimmune2.2384 of 5 stars$4.03-1.2%$18.20+351.5%-40.7%$326.95M$20K-3.2050Upcoming EarningsAVIRAtea Pharmaceuticals1.6961 of 5 stars$3.80-2.5%$6.00+57.9%-4.4%$325.29MN/A-2.3070News CoverageUpcoming EarningsALLOAllogene Therapeutics2.9848 of 5 stars$1.47-2.3%$8.44+476.4%-60.6%$320.44M$20K-1.19310News CoverageUpcoming EarningsALDXAldeyra Therapeutics1.4083 of 5 stars$5.32+2.9%$9.50+78.6%+29.6%$318.67MN/A-5.4810Upcoming EarningsCRVSCorvus Pharmaceuticals1.9043 of 5 stars$4.66-1.2%$15.00+222.2%+37.1%$317.33MN/A-4.7530Upcoming Earnings Related Companies and Tools Related Companies CADL Competitors GLUE Competitors ABEO Competitors RCKT Competitors OLMA Competitors ALT Competitors AVIR Competitors ALLO Competitors ALDX Competitors CRVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
